Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients

Koilubaeva Gulazyk Malikovna; Bolotbekova Altynai Maratovna; Egorova Olga Nikolaevna; Tarasova Galina Michailovna; Sarybaev Akbai Shogaipovich; Chukubaev Marat Abdyganovich; Turdukulov Zamir Ergeshevich; Usupbaeva Dinara Abulmeizovna; Turusbekova Aijan Kemelovna

doi:doi:10.11648/j.sjcm.20221101.13

Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients

Koilubaeva Gulazyk Malikovna, Bolotbekova Altynai Maratovna, Egorova Olga Nikolaevna, Tarasova Galina Michailovna, Sarybaev Akbai Shogaipovich, Chukubaev Marat Abdyganovich, Turdukulov Zamir Ergeshevich, Usupbaeva Dinara Abulmeizovna, Turusbekova Aijan Kemelovna

Published in Science Journal of Clinical Medicine (Volume 11, Issue 1)

Received: 4 January 2022 Accepted: 4 February 2022 Published: 16 February 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Monitoring of clinical and laboratory Takayasu's arteritis (TAK) activity was carried out in 40 patients. Most of them were female patients (92.5%), of Kyrgyz nationality (97.5%), of young age (median - 32 years [24; 44]), with a disease duration of 7.5 years (median – (3.5; 12.5)), with the onset of the disease at 24 years (median –(19; 30)), with V anatomical type - (72.5%), which had vascular stage (77.5%), III grade (≥2) of vascular complications (37.5%), severe exacerbation (65%), with pronounced activity (92.5%) according to the EULAR criteria, high laboratory activity (accelerated ESR in 75% and increased hsCRP - in 65.71% of patients). The lesion of the common carotid (85%) and subclavian arteries (85%) prevailed, the renal arteries were the second most frequently (62.5%) affected vessels, with a predominance of bilateral stenosis (96.1%). During the 5.5 year- follow-up course, a statistically significant partial remission (according to the BVAS index) was achieved in only 12.5% of patients, while frequency of mild and severe exacerbations of the disease remained at the same level (p> 0.05). However, according to the EULAR criteria, there was a statistically significant decrease in the disease activity (from 92.5% to 65% cases) and an increase in the frequency of remission (from 2.5% to 27.5% cases), with the exception of episodes of relapses: major (12.5%) and minor ones (45%).

Published in	Science Journal of Clinical Medicine (Volume 11, Issue 1)
DOI	10.11648/j.sjcm.20221101.13
Page(s)	14-24
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Takayasu's Arteritis, Disease Activity, Angiography, Doppler Ultrasound, Tomography, Monitoring

References

[1]	Jennette J., Falk R., Bacon P., et al. 2012 revised Internatoinal Chappel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65 (1): 1-11. Doi: 10.1002/art.37715.
[2]	Johnston S. L., Lock R. J., Gompels M. M. Takayasu arteritis: a review. J. Clin. Pathol., 2002; 55 (7): 481–486. doi: 10.1136/jcp.55.7.481.
[3]	Watts R., Al-Taiar A., Mooney J. et al. The epidemiology of Takayasu arteritis in the UK. Rheumatology, 2009; 48 (8): 1008–1011.
[4]	Hall S., Barr W., Lie JT., et al. Takayasu arteritis. A study of 32 North American patients. Medicine, 1985; 64: 89–99.
[5]	Bicakcigil M., Aksu K., Kamali S., Ozbalkan Z., Ates A., Karadag O., et al. Takayasu's arteritis in Turkey: clinical and angiographic features of 248 patients. Clin. Exp. Rheumatol., 2009; 27 Suppl 52: 59–64.
[6]	Karageorgaki Z. T., Bertsias G. K., Mavragani C. P. et al. Takayasu Features in Greece. Clin. Exp. Rheumotol., 2009; 27 (1): 833–839.
[7]	Saritas F, Donmez S, Direskeneli H, Pamuk ON. The epidemiology of Takayasu arteritis: a hospital-based study from northwestern part of Turkey. Rheumatol Int. 2016; 36 (7): 911–6. https://doi.org/10. 1007/s00296-016-3445-z PMID: 26936260.
[8]	Koide K. Takayasu arteritis in Japan. Heart Vessels Suppl. 1992; 7: 48–54. https://doi.org/10.1007/ BF01744544 PMID: 1360971.
[9]	Toshihiko N. Current status of large and small vessel vasculitis in Japan. Int. J Cardiol. 1996; 54 Suppl: S91–8. https://doi.org/10.1016/s0167-5273(96)88777-8 PMID: 911953.
[10]	Onen F, Akkoc N. Epidemiology of Takayasu arteritis. Presse Med. 2017; 46 (7–8 Pt 2): e197–e203. https://doi.org/10.1016/j.lpm.2017.05.034 PMID: 28756072.
[11]	Mohammad AJ, Mandl T. Takayasu arteritis in southern Sweden. J Rheumatol. 2015; 42 (5): 853–8. https://doi.org/10.3899/jrheum.140843 PMID: 25774057.
[12]	Moriwaki R., Noda M., Yajima M. et al. Clinical manifestations of Takayasu arteritis in India and Japan-new classification of angiographic findings. Angiology, 1997; 48 (5): 369–379.
[13]	Watanabe Y., Miyata T., Tanemoto K. Current clinical features of new patients with takayasu arteritis observed from cross-country research in Japan: age and sex specificity. Circulation, 2015; 132: 17019. doi: 10.1161/CIRCULATIONAHA.114.012547.
[14]	Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994; 120 (11): 919–29. https://doi.org/10.7326/0003-4819-120-11-199406010-00004 PMID: 7909656.
[15]	Hoffman G. S., Ahmed A. E. Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol., 1998; 66: 191-194.
[16]	Dagna L., Salvo F., Tiraboschi M. et al. Pentraxin-3 as a marker of disease activity in takayasu arteritis. Ann. Intern. Med., 2011; 155 (7): 425–433.
[17]	Ishihara T., Haraguchi G., Kamiishi T. et al. Sensitive assessment of activity of Takayasu’s arteritis by pentraxin3, a new biomarker. J. Am Coll. Cardiol., 2011; 57 (16): 1712–1713.
[18]	Direskeneli H., Aydin S. Z., Merkel P. A. Assessment of disease activity and progression in Takayas’s arteritis. Clin Exp Rheumatolog.; 29 Suppl 64: 86-91.
[19]	Li Cavoli G., Mulè G., Vallone MG., Caputo F. Takayasu’s disease effects on the kidneys: current perspectives. Internatoinal Journal of Nephrology and Renovascular disease, 2018; 11: 225-233. https://doi.org/10.2147/IJNRD.S146355.
[20]	Arend W. P., Michel B. A., Bloch D. A. et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum., 1990; 33 (8): 1129–1134.
[21]	Sharma B. K., Jain S., Suri S. et al. Diagnostic criteria for Takayasu arteritis. Int. J. Cardiol., 1996; 54: 141–S147.
[22]	North American Symptomatic Carotid Endar-terectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N. Engl. J. Med. 1991; 325: 445–53.
[23]	Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998; 351 (9113): 1379–87.
[24]	Bernhard Hellmich, Ana Agueda, Sara Monti et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis., 2020; 79: 19-30. Doi: 10.1136/annrheumdis-2019-215672.
[25]	Hata A., Noda M., Moriwaki R. et al. Angiographic findings of Takayasu arteritis: new classification. Int. J. Cardiol., 1996 (54): 155–S163.
[26]	Luqmani R. Evaluation of vasculitis disease activity in Europe. Eur J Intern Med., 2007; 66 (3): 283-292.
[27]	Jefferson R., Roberts M. D. et al. Takayasu Arteritis Differential Diagnoses. Medscape-2016 URL: http://emedicine.medscape.com/article/332378-differential.
[28]	Ishikawa K. Natural history and classification of occlusive thromboaortopathy (Takayasu’s disease). Circulation, 1978; 57 (1): 27–35.
[29]	Moriwaki R, Numano F. Takayasu arteritis: follow-up studies for 20 years. Heart and Vessels. 1992; 7 (1, supplement): 138–145.
[30]	Cieślik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity. 2012; 45 (2): 119–128.
[31]	Eichhorn J, Sima D, Thiele B, et al. Anti-endothelial cell antibodies in Takayasu arteritis. Circulation. 1996; 94 (10): 2396–2401.
[32]	Wang H, Ma J, Wu Q, Luo X, Chen Z, Kou L. Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. Journal of Vascular Surgery. 2011; 53 (1): 174–180.
[33]	Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis and Rheumatism. 2007; 56 (3): 1000–1009.
[34]	L. Watson, P. Brogan, I. Peart, C. et al. Diagnosis and Assessment of Disease Activity in Takayasu Arteritis: A Childhood Case Illustrating the Challenge. Case Rep Rheumatolog., 2014: 603171. Doi: 10.1155/2014/603171.
[35]	Schneeweis C, Schnackenburg B, Stuber M, et al. Delayed contrast-enhanced MRI of the coronary artery wall in takayasu arteritis. PLoS One. 2012; 7e50655.
[36]	Yamada I, Nakagawa T, Himeno Y, Kobayashi Y, Numano F, Shibuya H: Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging. 2000, 11: 481-7. 10.1002/(SICI)1522-2586(200005)11:5<481: AID-JMRI3>3.0.CO;2-4.
[37]	Maurizio Papa, Francesco De Cobelli, Elena Baldissera, et al. Takayasu Arteritis: Intravascular Contrast Medium for MR Angiography in the Evaluation of Disease Activity. AJR; 198, 2012: 279-284. DOI: 10.2214/AJR.11.7360.
[38]	Papa M, De Cobelli F, Baldissera E, et al. Takayasu arteritis: intravascular contrast medium for MR angiography in the evaluation of disease activity. American Journal of Roentgenology. 2012; 198 (3): W279–W284.
[39]	Eshet Y, Pauzner R, Goitein O, et al. The limited role of MRI in long-term follow-up of patients with Takayasu’s arteritis. Autoimmunity Reviews. 2011; 11: 132–136.
[40]	Yadav MK. Takayasu arteritis: clinical and CT—angiography profile of 25 patients and a brief review of literature. Indian Heart Journal. 2007; 59 (6): 468–474.
[41]	Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases. 2009; 68 (3): 318–323.

Cite This Article

Plain Text BibTeX RIS

APA Style

Koilubaeva Gulazyk Malikovna, Bolotbekova Altynai Maratovna, Egorova Olga Nikolaevna, Tarasova Galina Michailovna, Sarybaev Akbai Shogaipovich, et al. (2022). Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients. Science Journal of Clinical Medicine, 11(1), 14-24. https://doi.org/10.11648/j.sjcm.20221101.13

Copy | Download

ACS Style

Koilubaeva Gulazyk Malikovna; Bolotbekova Altynai Maratovna; Egorova Olga Nikolaevna; Tarasova Galina Michailovna; Sarybaev Akbai Shogaipovich, et al. Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients. Sci. J. Clin. Med. 2022, 11(1), 14-24. doi: 10.11648/j.sjcm.20221101.13

Copy | Download

AMA Style

Koilubaeva Gulazyk Malikovna, Bolotbekova Altynai Maratovna, Egorova Olga Nikolaevna, Tarasova Galina Michailovna, Sarybaev Akbai Shogaipovich, et al. Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients. Sci J Clin Med. 2022;11(1):14-24. doi: 10.11648/j.sjcm.20221101.13

Copy | Download

@article{10.11648/j.sjcm.20221101.13,
  author = {Koilubaeva Gulazyk Malikovna and Bolotbekova Altynai Maratovna and Egorova Olga Nikolaevna and Tarasova Galina Michailovna and Sarybaev Akbai Shogaipovich and Chukubaev Marat Abdyganovich and Turdukulov Zamir Ergeshevich and Usupbaeva Dinara Abulmeizovna and Turusbekova Aijan Kemelovna},
  title = {Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients},
  journal = {Science Journal of Clinical Medicine},
  volume = {11},
  number = {1},
  pages = {14-24},
  doi = {10.11648/j.sjcm.20221101.13},
  url = {https://doi.org/10.11648/j.sjcm.20221101.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20221101.13},
  abstract = {Monitoring of clinical and laboratory Takayasu's arteritis (TAK) activity was carried out in 40 patients. Most of them were female patients (92.5%), of Kyrgyz nationality (97.5%), of young age (median - 32 years [24; 44]), with a disease duration of 7.5 years (median – (3.5; 12.5)), with the onset of the disease at 24 years (median –(19; 30)), with V anatomical type - (72.5%), which had vascular stage (77.5%), III grade (≥2) of vascular complications (37.5%), severe exacerbation (65%), with pronounced activity (92.5%) according to the EULAR criteria, high laboratory activity (accelerated ESR in 75% and increased hsCRP - in 65.71% of patients). The lesion of the common carotid (85%) and subclavian arteries (85%) prevailed, the renal arteries were the second most frequently (62.5%) affected vessels, with a predominance of bilateral stenosis (96.1%). During the 5.5 year- follow-up course, a statistically significant partial remission (according to the BVAS index) was achieved in only 12.5% of patients, while frequency of mild and severe exacerbations of the disease remained at the same level (p> 0.05). However, according to the EULAR criteria, there was a statistically significant decrease in the disease activity (from 92.5% to 65% cases) and an increase in the frequency of remission (from 2.5% to 27.5% cases), with the exception of episodes of relapses: major (12.5%) and minor ones (45%).},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients
AU  - Koilubaeva Gulazyk Malikovna
AU  - Bolotbekova Altynai Maratovna
AU  - Egorova Olga Nikolaevna
AU  - Tarasova Galina Michailovna
AU  - Sarybaev Akbai Shogaipovich
AU  - Chukubaev Marat Abdyganovich
AU  - Turdukulov Zamir Ergeshevich
AU  - Usupbaeva Dinara Abulmeizovna
AU  - Turusbekova Aijan Kemelovna
Y1  - 2022/02/16
PY  - 2022
N1  - https://doi.org/10.11648/j.sjcm.20221101.13
DO  - 10.11648/j.sjcm.20221101.13
T2  - Science Journal of Clinical Medicine
JF  - Science Journal of Clinical Medicine
JO  - Science Journal of Clinical Medicine
SP  - 14
EP  - 24
PB  - Science Publishing Group
SN  - 2327-2732
UR  - https://doi.org/10.11648/j.sjcm.20221101.13
AB  - Monitoring of clinical and laboratory Takayasu's arteritis (TAK) activity was carried out in 40 patients. Most of them were female patients (92.5%), of Kyrgyz nationality (97.5%), of young age (median - 32 years [24; 44]), with a disease duration of 7.5 years (median – (3.5; 12.5)), with the onset of the disease at 24 years (median –(19; 30)), with V anatomical type - (72.5%), which had vascular stage (77.5%), III grade (≥2) of vascular complications (37.5%), severe exacerbation (65%), with pronounced activity (92.5%) according to the EULAR criteria, high laboratory activity (accelerated ESR in 75% and increased hsCRP - in 65.71% of patients). The lesion of the common carotid (85%) and subclavian arteries (85%) prevailed, the renal arteries were the second most frequently (62.5%) affected vessels, with a predominance of bilateral stenosis (96.1%). During the 5.5 year- follow-up course, a statistically significant partial remission (according to the BVAS index) was achieved in only 12.5% of patients, while frequency of mild and severe exacerbations of the disease remained at the same level (p> 0.05). However, according to the EULAR criteria, there was a statistically significant decrease in the disease activity (from 92.5% to 65% cases) and an increase in the frequency of remission (from 2.5% to 27.5% cases), with the exception of episodes of relapses: major (12.5%) and minor ones (45%).
VL  - 11
IS  - 1
ER  -

Copy | Download

Author Information

Koilubaeva Gulazyk Malikovna

National Centre of Cardiology and Internal Medicine (NCIIM), Bishkek, the Kyrgyz Republic
Bolotbekova Altynai Maratovna

National Centre of Cardiology and Internal Medicine (NCIIM), Bishkek, the Kyrgyz Republic
Egorova Olga Nikolaevna

Research Institute of Rheumatology Named After V. A. Nasonova Federal State Budgetary Institution, Moscow, the Russian Federation
Tarasova Galina Michailovna

Research Institute of Rheumatology Named After V. A. Nasonova Federal State Budgetary Institution, Moscow, the Russian Federation
Sarybaev Akbai Shogaipovich

National Centre of Cardiology and Internal Medicine (NCIIM), Bishkek, the Kyrgyz Republic
Chukubaev Marat Abdyganovich

National Centre of Cardiology and Internal Medicine (NCIIM), Bishkek, the Kyrgyz Republic
Turdukulov Zamir Ergeshevich

National Centre of Cardiology and Internal Medicine (NCIIM), Bishkek, the Kyrgyz Republic
Usupbaeva Dinara Abulmeizovna

National Centre of Cardiology and Internal Medicine (NCIIM), Bishkek, the Kyrgyz Republic
Turusbekova Aijan Kemelovna

National Centre of Cardiology and Internal Medicine (NCIIM), Bishkek, the Kyrgyz Republic

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Koilubaeva Gulazyk Malikovna, Bolotbekova Altynai Maratovna, Egorova Olga Nikolaevna, Tarasova Galina Michailovna, Sarybaev Akbai Shogaipovich, et al. (2022). Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients. Science Journal of Clinical Medicine, 11(1), 14-24. https://doi.org/10.11648/j.sjcm.20221101.13

Copy | Download

ACS Style

Koilubaeva Gulazyk Malikovna; Bolotbekova Altynai Maratovna; Egorova Olga Nikolaevna; Tarasova Galina Michailovna; Sarybaev Akbai Shogaipovich, et al. Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients. Sci. J. Clin. Med. 2022, 11(1), 14-24. doi: 10.11648/j.sjcm.20221101.13

Copy | Download

AMA Style

Koilubaeva Gulazyk Malikovna, Bolotbekova Altynai Maratovna, Egorova Olga Nikolaevna, Tarasova Galina Michailovna, Sarybaev Akbai Shogaipovich, et al. Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients. Sci J Clin Med. 2022;11(1):14-24. doi: 10.11648/j.sjcm.20221101.13

Copy | Download

@article{10.11648/j.sjcm.20221101.13,
  author = {Koilubaeva Gulazyk Malikovna and Bolotbekova Altynai Maratovna and Egorova Olga Nikolaevna and Tarasova Galina Michailovna and Sarybaev Akbai Shogaipovich and Chukubaev Marat Abdyganovich and Turdukulov Zamir Ergeshevich and Usupbaeva Dinara Abulmeizovna and Turusbekova Aijan Kemelovna},
  title = {Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients},
  journal = {Science Journal of Clinical Medicine},
  volume = {11},
  number = {1},
  pages = {14-24},
  doi = {10.11648/j.sjcm.20221101.13},
  url = {https://doi.org/10.11648/j.sjcm.20221101.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20221101.13},
  abstract = {Monitoring of clinical and laboratory Takayasu's arteritis (TAK) activity was carried out in 40 patients. Most of them were female patients (92.5%), of Kyrgyz nationality (97.5%), of young age (median - 32 years [24; 44]), with a disease duration of 7.5 years (median – (3.5; 12.5)), with the onset of the disease at 24 years (median –(19; 30)), with V anatomical type - (72.5%), which had vascular stage (77.5%), III grade (≥2) of vascular complications (37.5%), severe exacerbation (65%), with pronounced activity (92.5%) according to the EULAR criteria, high laboratory activity (accelerated ESR in 75% and increased hsCRP - in 65.71% of patients). The lesion of the common carotid (85%) and subclavian arteries (85%) prevailed, the renal arteries were the second most frequently (62.5%) affected vessels, with a predominance of bilateral stenosis (96.1%). During the 5.5 year- follow-up course, a statistically significant partial remission (according to the BVAS index) was achieved in only 12.5% of patients, while frequency of mild and severe exacerbations of the disease remained at the same level (p> 0.05). However, according to the EULAR criteria, there was a statistically significant decrease in the disease activity (from 92.5% to 65% cases) and an increase in the frequency of remission (from 2.5% to 27.5% cases), with the exception of episodes of relapses: major (12.5%) and minor ones (45%).},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Takayasu's Arteritis: Monitoring of Clinical and Laboratory Activity in a Kyrgyz Cohort of Patients
AU  - Koilubaeva Gulazyk Malikovna
AU  - Bolotbekova Altynai Maratovna
AU  - Egorova Olga Nikolaevna
AU  - Tarasova Galina Michailovna
AU  - Sarybaev Akbai Shogaipovich
AU  - Chukubaev Marat Abdyganovich
AU  - Turdukulov Zamir Ergeshevich
AU  - Usupbaeva Dinara Abulmeizovna
AU  - Turusbekova Aijan Kemelovna
Y1  - 2022/02/16
PY  - 2022
N1  - https://doi.org/10.11648/j.sjcm.20221101.13
DO  - 10.11648/j.sjcm.20221101.13
T2  - Science Journal of Clinical Medicine
JF  - Science Journal of Clinical Medicine
JO  - Science Journal of Clinical Medicine
SP  - 14
EP  - 24
PB  - Science Publishing Group
SN  - 2327-2732
UR  - https://doi.org/10.11648/j.sjcm.20221101.13
AB  - Monitoring of clinical and laboratory Takayasu's arteritis (TAK) activity was carried out in 40 patients. Most of them were female patients (92.5%), of Kyrgyz nationality (97.5%), of young age (median - 32 years [24; 44]), with a disease duration of 7.5 years (median – (3.5; 12.5)), with the onset of the disease at 24 years (median –(19; 30)), with V anatomical type - (72.5%), which had vascular stage (77.5%), III grade (≥2) of vascular complications (37.5%), severe exacerbation (65%), with pronounced activity (92.5%) according to the EULAR criteria, high laboratory activity (accelerated ESR in 75% and increased hsCRP - in 65.71% of patients). The lesion of the common carotid (85%) and subclavian arteries (85%) prevailed, the renal arteries were the second most frequently (62.5%) affected vessels, with a predominance of bilateral stenosis (96.1%). During the 5.5 year- follow-up course, a statistically significant partial remission (according to the BVAS index) was achieved in only 12.5% of patients, while frequency of mild and severe exacerbations of the disease remained at the same level (p> 0.05). However, according to the EULAR criteria, there was a statistically significant decrease in the disease activity (from 92.5% to 65% cases) and an increase in the frequency of remission (from 2.5% to 27.5% cases), with the exception of episodes of relapses: major (12.5%) and minor ones (45%).
VL  - 11
IS  - 1
ER  -

Copy | Download